Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Boston Scientific (BSX) is attracting bullish analyst attention after its strategic acquisition of Penumbra, with Truist Securities reiterating a Buy rating and a $120 price target, citing enhanced business durability and growth prospects.
Despite a challenging mortgage landscape and specific credit headwinds, Hilltop Holdings Inc. (HTH) reported a 46% surge in annual net income for 2025, buoyed by a steepening yield curve and disciplined cost management across its banking, lending, and securities divisions.
Rosenblatt Securities initiates coverage on Credo Technology with a Neutral rating and a $170 price target, highlighting its strong position in high-speed connectivity for AI infrastructure while flagging competitive pressures. The note follows a more bullish target hike from Barclays earlier in the month.
Analyst firm Piper Sandler reiterates its Overweight rating on AGNC Investment Corp., highlighting a favorable shift in agency mortgage-backed securities spreads that could bolster the REIT's book value.
Truist Securities has slightly lowered its price target on Tesla shares to $438, citing the significant capital expenditure required for the automaker's aggressive shift towards AI and robotics, despite a solid Q4 performance.
Truist Securities has lowered its price target on Landstar System (LSTR) from $150 to $145, maintaining a Hold rating following the logistics provider's fourth-quarter earnings miss. Analysts cite one-time insurance costs as a drag, while noting core fundamentals have yet to show a decisive turnaround.
Truist Securities raises its price target on Meta Platforms to $900, maintaining a Buy rating. The upgrade follows stronger-than-expected Q4 results and a robust Q1 outlook, driven by AI enhancements boosting ad performance and user engagement.
Analysts at Truist Securities have adjusted their outlook for Packaging Corporation of America (PKG), lowering the price target to $270 following a fourth-quarter earnings miss. Despite the revision, the firm reiterates its Buy rating, suggesting the recent stock dip may present a strategic buying opportunity ahead of anticipated strength in the packaging sector.
AI cloud provider CoreWeave faces a critical juncture as a massive equity investment from chip giant Nvidia clashes with securities class actions alleging the company misled investors about its operational capacity and supplier dependencies.
Blue Owl Capital faces a wave of securities class actions alleging disclosure failures around liquidity and redemptions, casting a shadow over its robust alternative asset management platform. As legal pressures mount, the market weighs solid analyst backing against growing governance concerns, setting the stage for a pivotal earnings report.
Southside Bancshares (SBSI) reported a significant rebound in fourth-quarter earnings, driven by strategic repositioning of its securities portfolio and lower funding costs. While loan growth remained modest, executives outlined a cautious outlook for near-term margin improvement and detailed plans for technology investments and selective M&A in competitive Texas markets.
Bank of America Securities has reaffirmed its Buy rating on Hesai Group (HSAI), raising its price target to $32, citing the lidar maker's technological milestones, strategic partnership with NVIDIA, and favorable regulatory developments for autonomous driving.
Truist Securities has raised its price target for Amer Sports (NYSE: AS), citing the company's clear long-term roadmap and 'durable growth levers' across its portfolio of iconic sports brands. The firm sees a realistic path to earnings per share exceeding $2.50 by fiscal 2030.
Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.
Shares of Meta Platforms soared Thursday, fueled by a significant price target upgrade from BofA Securities. The rally comes despite the company reporting a slight dip in full-year profit, as investors focus on strong revenue growth and the company's positioning in the artificial intelligence race.
As Japan heads to the polls, Prime Minister Sanae Takaichi's expansionary fiscal pledges are being put to the test in a critical 30-year bond auction, with investors wary of the nation's towering debt burden.
Deutsche Bank has upgraded AI infrastructure provider CoreWeave to 'Buy,' significantly raising its price target to $140, citing a strong medium-term outlook and capacity expansion plans backed by a deepened partnership with Nvidia.
Haemonetics (NYSE:HAE) sees its price target raised by Barrington Research following its acquisition of Vivasure Medical, with analysts highlighting the deal's potential to bolster its medical device portfolio and drive growth.
A sharp sell-off in Microsoft shares following its earnings report has ignited fresh fears over the profitability of massive AI investments, pulling major indexes lower and pushing the software sector into a bear market.
